What is Naxitamab injection?

Naxitamab injection (Naxitamab) is an anti-cancer drug with the trade name Danyelza. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF)for use in patients 1 year of age and older with relapsed or refractory high-risk neuroblastoma of the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

The application for nocetumumab injection was approved based on two clinical trials (Trial 1/NCT03363373 and Trial 2/NCT01757626) of 97 participants with high-risk neuroblastoma in the bone or bone marrow. Both trials enrolled participants who had been previously treated for high-risk neuroblastoma in the bone or bone marrow. Some participants no longer responded to previous treatments, and some experienced cancer recurrence. Participants whose cancer became active after their last treatment were not included in the trial. According to the trial plan, all participants received a combination of noxituzumab injection and granulocyte-macrophage colony-stimulating factor (GM-CSF).

The most common adverse reactions of nacertuzumab injection include infusion-related reactions, pain, tachycardia (fast heartbeat), vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, fever, headache, injection site reaction, edema, anxiety, local edema, and irritability.

It is understood that noxituzumab injection has been approved in China, but it has not been included in medical insurance. Its price is still unclear and the purchase method is difficult. The original drug of Naxituzumab injection marketed overseas is very expensive, and the price may fluctuate due to exchange rates. For more drug information and specific prices, please consult a medical consultant.